Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

Centre de recherche du Centre hospitalier universitaire de Sherbrooke2,120 enrolled

Overview

Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE injection in patients with suspected or diagnosed with tumors expressing somatostatin receptors. Each included patient will receive an administered dose of 50 mcg or less of the peptide (DOTA-TATE) and a range of activity between 100 - 200 MBq of 68Ga-DOTA-TATE. The efficacy of 68Ga-DOTA-TATE in assessing this kind of tumors has been proved by numerous studies.

Study Type

OBSERVATIONAL

Enrollment

2,120

Conditions

Neuroendocrine Tumors

Interventions

Gallium-68 DOTA TATE PET scanOTHER

One PET/CT scan using Gallium-68 DOTA TATE

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with suspected or proven tumors expressing Somatostatin receptors 2. Informed consent by patient (or parents if patient is less than 18 years of age) Exclusion Criteria: 1. Pregnancy (confirmed). In the case of a diagnostic procedure in a patient who is or may be pregnant, a clinical decision is necessary considering the benefits against the possible harm of carrying out any procedure. 2. Patient refusal to participate. 3. Impossibility to tolerate a decubitus position for 25 minutes 4. Prior allergic reaction to DOTA-TATE or somatostatin analogs

Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes